Clinical trials: Anal Cancer
Prostate Carcinoma, Rectum Carcinoma
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation
Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when…
- Conditions
- Prostate Carcinoma, Rectum Carcinoma, Anal Canal Carcinoma, Endometrium Carcinoma
- Trial name
- MIFADORESOL (NCT04626466)
- Testing
- Biological investigations
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started…
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Trial name
- NCT02314169
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 56 sites in United States, Canada
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Radiodermatitis, Injury, Radiation
Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.
This is a randomized, open-label, single-institution trial designed to evaluate the effectiveness of a spray skin protector in preventing moist desquamation caused by radiotherapy treatment.
- Trial name
- NCT04067310
- Testing
- Spray skin protector, moisturizer Dnativ Revita derm
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Anal Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.
- Conditions
- Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
- Trial name
- NCT01209325
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- AIDS Malignancy Consortium
Gastrointestinal Cancer (Esophagus, Gastric, Pancreatic, Hepatic, Colorectal and Anal), Lung Cancer
Evolution of Corporeal Composition in the PeriOperative Period
Denutrition and Obesity are risk factors for perioperative surgical complications. In patient with cancer, incidence of denutrition is markedly increased.
- Trial name
- ECCOP (NCT02143869)
- Testing
- Bioelectrical Impedance Analysis
- Where
- France
- Volunteers
- 374 people
- Sponsor
- Hôpital Européen Marseille
Low Anterior Resection Syndrome
Anal Dilatation Plus Probiotics Before Ileostomy Reduction for Low Anterior Resection Syndrome
This is randomized, phase 2 trial in patients with rectal cancer undergoing sphincter-preserving proctectomy and temporary ileostomy, to explore the effects of anal dilatation plus probiotics administered per anus before…
- Trial name
- PILLARS (NCT04688242)
- Testing
- Anal dilatation per anus, administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Anal Cancer, Colorectal Cancer
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea.
- Conditions
- Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
- Trial name
- NCT00075868
- Testing
- octreotide acetate
- Where
- 112 sites in United States
- Volunteers
- 233 people
- Sponsor
- Radiation Therapy Oncology Group
HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions
A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System
This is a Single-center prospective pilot trial involving up to 22 subjects. This study will assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal canal using the FDA cleared HALO Ablation…
- Trial name
- AIN (NCT01970787)
- Testing
- Radiofrequency Ablation (RFA) using the HALO Ablation System
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medtronic - MITG
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor…
- Conditions
- Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer
- Trial name
- Tamarack (NCT05551117)
- Testing
- vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 192 people
- Sponsor
- MacroGenics
HIV-Associated Malignant Neoplasm, HIV Infections
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in…
- Conditions
- HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma
- Trial name
- NCT05510908
- Testing
- Non-Interventional, Non-Interventional Follow-up
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 460 people
- Sponsor
- AIDS Malignancy Consortium
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
HPV Testing
Study on Anal Human Papillomavirus Infection and Anal Intraepithelial Neoplasia Among Men Who Have Sex With Men in Indonesia, Malaysia, and Thailand
OBJECTIVES 1. To determine the prevalence and incidence of anal HPV infection, including infection with high-risk HPV types, among MSM in Indonesia, Malaysia, and Thailand. 2.
- Trial name
- NCT02155231
- Where
- Thailand
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
- Trial name
- NCT06949800
- Testing
- EXE-346 Probiotic, Usual Care High Resolution Anoscopy (HRA)
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- University of California, San Francisco
Anal Cancer
A Study Regarding Tissue Response During and After Treatment for Anal Cancer
The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: The tumour microenvironment The localisation of and cellular interactions…
- Trial name
- ANCABio (NCT05939401)
- Testing
- Biopsies
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Human Papillomavirus Infection
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
This study is to demonstrate that the administration of the investigational vaccine can reduce the Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3)…
- Trial name
- NCT05668572
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
- Where
- 3 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
HPV-induced Cancers
Immune Therapy of HPV-induced Cancers
Patients with advanced HPV- and p16INK4a-positive cancers will receive the peptide P16_37-63 in combination with Montanide® ISA-51 VG so that an immune response directed against the tumor cells can be induced.
- Trial name
- NCT01462838
- Testing
- P16_37-63
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Oryx GmbH & Co. KG
Melanoma, Non-small Cell Lung Cancer
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04596033
- Testing
- GEN-011, IL-2, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genocea Biosciences, Inc.
Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
Over 80% of anal cancers are squamous cell carcinoma (SCC). Current standard treatment for locally advanced squamous cell carcinoma of the anal canal is a combination of radiation therapy (RT) and concurrent chemotherapy.
- Trial name
- NCT03386500
- Testing
- BMX-001
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Anal Cancer
Shared Decision Making With Anal Cancer Patients on Radiation Dose
The purpose of this study is to maximize patient involvement in the treatment of anal cancer. Specifically, the investigators will investigate whether patients wish to take part in the decision making on radiation dose and…
- Trial name
- PC-Anal-01 (NCT02785263)
- Testing
- 2.15 gray and 1.8 gray. Max. 6 weeks., 2.15 gray and 1.8 gray. Max. 5 weeks.
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Vejle Hospital